Cost-utility analyses of cognitive-behavioural therapy of depression: A systematic review

Psychotherapy and Psychosomatics

Volumn 84, Issue 1, 2015, Pages 6-21

  Brettschneider, Christian ^a   Djadran, Helei ^a   Härter, Martin ^a   Löwe, Bernd ^a   Riedel Heller, Steffi ^b   König, Hans Helmut ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

Cognitive behavioural therapy; Cost utility analysis; Health care utilization; Health related quality of life; Major depressive disorder

Indexed keywords

COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; COST UTILITY ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MAINTENANCE THERAPY; MAJOR DEPRESSION; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); RELAPSE; REVIEW; SHORT COURSE THERAPY; SYSTEMATIC REVIEW; ADOLESCENT; ADULT; COST BENEFIT ANALYSIS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; ECONOMICS; FEMALE; MALE; MIDDLE AGED; PROCEDURES;

ADOLESCENT; ADULT; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; MIDDLE AGED; QUALITY-ADJUSTED LIFE YEARS;

EID: 84922263602     PISSN: 00333190     EISSN: 14230348     Source Type: Journal    
DOI: 10.1159/000365150     Document Type: Review

References (54)

1. Vos T, Flaxman AD, Naghavi M, et al: Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2163-2196
2. Murray CJ, Vos T, Lozano R: Disability-Adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2197-2223
3. National Institute for Health and Clinical Excellence: CG28: Depression in Children and Young People: NICE Guideline. London , National Institute for Health and Clinical Excellence, 2010
4. National Institute for Health and Clinical Excellence: CG90: Depression in Adults: NICE Guideline. London , National Institute for Health and Clinical Excellence, 2013
5. American Psychiatric Association (APA): Practice Guideline for the Treatment of Patients with Major Depressive Disorder, ed 3. Arlington, VA, American Psychiatric Association (APA), 2010
6. US Preventive Services Task Force: Screening and treatment for major depressive disorder in children and adolescents: US Preventive Services Task Force recommendation statement. Pediatrics 2009; 123: 1223-1228
7. Gould RL, Coulson MC, Howard RJ: Cognitive behavioral therapy for depression in older people: a meta-Analysis and meta-regression of randomized controlled trials. J Am Geriatr Soc 2012; 60: 1817-1830
8. Cuijpers P, Berking M, Andersson G, Quigley L, Kleiboer A, Dobson KS: A meta-Analysis of cognitive-behavioural therapy for adult depression, alone and in comparison with other treatments. Can J Psychiatry 2013; 58: 376-385
9. Scope A, Leaviss J, Kaltenhaler E, Parry G, Sutcliffe P, Bradburn M, Cantrell A: Is group cognitive behaviour therapy for postnatal depression evidence-based practice?. A systematic review. BMC Psychiatry 2013; 13: 321
10. Hofmann SG, Asmundson GJ, Beck AT: The science of cognitive therapy. Behav Ther 2013; 44: 199-212
11. VersorgungsLeitlinien Ärztliches Zentrum für Qualität in der Medizin (ÄZQ): S3-Guideline/ National Disease Management Guideline Unipolar Depression. Berlin, ÄZQ, 2013
12. Konnopka A, Schaefert R, Heinrich S, Kaufmann C, Luppa M, Herzog W, König HH: Economics of medically unexplained symptoms: a systematic review of the literature. Psychother Psychosom 2012; 81: 265-275
13. OECD iLibrary: OECD Health Data: Economic References. 2014 . 24.03.2014 .
14. International Monetary Fund: World Economic Outlook Database, October 2013 Edition. 2013. 24.03.2014 .
15. Havrilesky LJ, Pokrzywinski R, Revicki D, Higgins RV, Nycum LR, Kohler MF, Berchuck A, Myers ER, Secord AA: Cost-effectiveness of combination versus sequential docetaxel and carboplatin for the treatment of platinum-sensitive, recurrent ovarian cancer. Cancer 2012; 118: 386-391
16. Chhatwal J, Ferrante SA, Brass C, El Khoury AC, Burroughs M, Bacon B, Esteban-Mur R, Elbasha EH: Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health 2013; 16: 973-986
17. Schoenbaum M, Denchev P, Vitiello B, Kaltman JR: Economic evaluation of strategies to reduce sudden cardiac death in young athletes. Pediatrics 2012; 130:e380-e389
18. Kristian B, Wachtmeister K, Stefan F, Forsgren L: Retigabine as add-on treatment of refractory epilepsy - A cost-utility study in a Swedish setting. Acta Neurol Scand 2013; 127: 419-426
19. Stuhldreher N, Konnopka A, Wild B, Herzog W, Zipfel S, Löwe B, König H: Cost-of-illness studies and cost-effectiveness analyses in eating disorders: a systematic review. Int J Eat Disord 2012; 45: 476-491
20. Vos T, Corry J, Haby MM, Carter R, Andrews G: Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. Aust NZ J Psychiatry 2005; 39: 683-692
21. Simon J, Pilling S, Burbeck R, Goldberg D: Treatment options in moderate and severe depression: decision analysis supporting a clinical guideline. Br J Psychiatry 2006; 189: 494-501
22. Sado M, Knapp M, Yamauchi K, Fujisawa D, So M, Nakagawa A, Kikuchi T, Ono Y: Costeffectiveness of combination therapy versus antidepressant therapy for management of depression in Japan. Aust NZ J Psychiatry 2009; 43: 539-547
23. Prukkanone B, Vos T, Bertram M, Lim S: Cost-effectiveness analysis for antidepressants and cognitive behavioral therapy for major depression in Thailand. Value Health 2012; 15(1 suppl):S3-S8
24. Revicki DA, Siddique J, Frank L, Chung JY, Green BL, Krupnick J, Prasad M, Miranda J: Cost-effectiveness of evidence-based pharmacotherapy or cognitive behavior therapy compared with community referral for major depression in predominantly low-income minority women. Arch Gen Psychiatry 2005; 62: 868-875
25. Morrell CJ, Warner R, Slade P, Dixon S, Walters S, Paley G, Brugha T: Psychological interventions for postnatal depression: cluster randomised trial and economic evaluation. The PoNDER trial. Health Technol Assess 2009; 13:iii-iv, xi-xiii, 1-153
26. Byford S, Barrett B, Roberts C, Wilkinson P, Dubicka B, Kelvin RG, White L, Ford C, Breen S, Goodyer I: Cost-effectiveness of selective serotonin reuptake inhibitors and routine specialist care with and without cognitive-behavioural therapy in adolescents with major depression. Br J Psychiatry 2007; 191: 521-527
27. Domino ME, Burns BJ, Silva SG, Kratochvil CJ, Vitiello B, Reinecke MA, Mario J, March JS: Cost-effectiveness of treatments for adolescent depression: results from tads. Am J Psychiatry 2008; 165: 588-596
28. Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS: Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the TADS randomized trial. J Am Acad Child Adolesc Psychiatry 2009; 48: 711-720
29. Goodyer IM, Dubicka B, Wilkinson P, Kelvin R, Roberts C, Byford S, Breen S, Ford C, Barrett B, Leech A, Rothwell J, White L, Harrington R: A randomised controlled trial of cognitive behaviour therapy in adolescents with major depression treated by selective serotonin reuptake inhibitors. The ADAPT trial. Health Technol Assess 2008; 12:iii-iv, ix-60
30. Lynch FL, Dickerson JF, Clarke G, Vitiello B, Porta G, Wagner KD, Emslie G, Asarnow JR Jr, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes T, DeBar L, McCracken JT, Strober M, Suddath RL, Spirito A, Onorato M, Zelazny J, Iyengar S, Brent D: Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry 2011; 68: 253-262
31. Haby MM, Tonge B, Littlefield L, Carter R, Vos T: Cost-effectiveness of cognitive behavioural therapy and selective serotonin reuptake inhibitors for major depression in children and adolescents. Aust NZ J Psychiatry 2004; 38: 579-591
32. Schoenbaum M, Unützer J, Sherbourne C, Duan N, Rubenstein LV, Miranda J, Meredith LS, Carney MF, Wells K: Cost-effectiveness of practice-initiated quality improvement for depression: results of a randomized controlled trial. JAMA 2001; 286: 1325-1330
33. Schoenbaum M, Miranda J, Sherbourne C, Duan N, Wells K: Cost-effectiveness of interventions for depressed Latinos. J Ment Health Policy Econ 2004; 7: 69-76
34. Schoenbaum M, Sherbourne C, Wells K: Gender patterns in cost effectiveness of quality improvement for depression: results of a randomized, controlled trial. J Affect Disord 2005; 87: 319-325
35. Stevenson MD, Scope A, Sutcliffe PA: The cost-effectiveness of group cognitive behavioral therapy compared with routine primary care for women with postnatal depression in the UK. Value Health 2010; 13: 580-584
36. Gerhards SA, de Graaf LE, Jacobs LE, Severens JL, Huibers MJ, Arntz A, Riper H, Widdershoven G, Metsemakers JF, Evers SM: Economic evaluation of online computerised cognitive-behavioural therapy without support for depression in primary care: randomised trial. Br J Psychiatry 2010; 196: 310-318
37. Hollinghurst S, Peters TJ, Kaur S, Wiles N, Lewis G, Kessler D: Cost-effectiveness of therapist-delivered online cognitive-behavioural therapy for depression: randomised controlled trial. Br J Psychiatry 2010; 197: 297-304
38. Warmerdam L, Smit F, van Straten A, Riper H, Cuijpers P: Cost-utility and cost-effectiveness of internet-based treatment for adults with depressive symptoms: randomized trial. J Med Internet Res 2010; 12:e53
39. Kaltenthaler E, Brazier J, De Nigris E, Tumur I, Ferriter M, Beverley C, Parry G, Rooney G, Sutcliffe P: Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess 2006; 10:iii, xi-xiv, 1-168
40. Lynch FL, Hornbrook M, Clarke GN, Perrin N, Polen MR, O'Connor E, Dickerson J: Costeffectiveness of an intervention to prevent depression in at-risk teens. Arch Gen Psychiatry 2005; 62: 1241-1248
41. Stant AD, Ten Vergert EM, Kluiter H, Conradi HJ, Smit A, Ormel J: Cost-effectiveness of a psychoeducational relapse prevention program for depression in primary care. J Ment Health Policy Econ 2009; 12: 195-204
42. Kessler RC, Birnbaum H, Bromet E, Hwang I, Sampson N, Shahly V: Age differences in major depression: results from the national comorbidity survey replication (NCS-R). Psychol Med 2010; 40: 225-237
43. Grosse SD: Assessing cost-effectiveness in healthcare: history of the 50, 000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 2008; 8: 165-178
44. Lee CP, Chertow GM, Zenios SA: An empiric estimate of the value of life: updating the renal dialysis cost-effectiveness standard. Value Health 2009; 12: 80-87
45. Eaton WW, Shao H, Nestadt G, Lee HB, Bienvenu OJ, Zandi P: Population-based study of first onset and chronicity in major depressive disorder. Arch Gen Psychiatry 2008; 65: 513-520
46. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD, Endicott J: Multiple recurrences of major depressive disorder. Am J Psychiatry 2000; 157: 229-233
47. Luppa M, Heinrich S, Angermeyer MC, Konig HH, Riedel-Heller SG: Cost-of-illness studies of depression: a systematic review. J Affect Disord 2007; 98: 29-43
48. Ekman M, Granstrom O, Omerov S, Jacob J, Landen M: The societal cost of depression: evidence from 10, 000 Swedish patients in psychiatric care. J Affect Disord 2013; 150: 790-797
49. Drummond MF, Sculpher MJ, Torrance GW, O'Brien BJ, Stoddart GL: Methods for the Economic Evaluation of Health Care Programmes, ed 3. Oxford, Oxford University Press, 2005
50. Luce BR, Manning WG, Siegel JE, Lipscomb J: Estimating costs in cost-effectiveness analysis; in Gold MR, Siegel JE, Russell L, Weinstein MC (eds): Cost-Effectiveness in Health and Medicine. Oxford, Oxford University Press, 1996
51. Haute Autorité de Santé: Choices in Methods for Economic Evaluation. Plaine-Saint-Denis, Haute Autorité de Santé, 2012
52. College voor Zorgverzekeringen: Guidelines for Pharmacoeconomic Research, Updated Version. Diemen, College voor Zorgverzekeringen, 2006
53. Belgian Health Care Knowledge Centre: Belgian Guidelines for Economic Evaluations and Budget Impact Analyses, ed 2. Brussels, Belgian Health Care Knowledge Centre, 2012
54. Institute for Quality and Efficiency in Health Care: General Methods for the Assessment of the Relation of Benefits to Costs. Cologne , Institute for Quality and Efficiency in Health Care (IQWiG), 2009